Research Article
The Fusion Oncogene FUS-CHOP Drives Sarcomagenesis of High-Grade Spindle Cell Sarcomas in Mice
Table 2
Mouse modeling approaches and tumor penetrance.
| | | CRISPR/Cre activation | Tumors | Total mice | Penetrance |
| | Tissue-specific Cre models | | Meox2-Cre, Rosa26 LSL-FUS-CHOP/+ | Endogenous Cre | Embryonic lethal | | PdgfRα-Cre, Rosa26 LSL-FUS-CHOP/+ | Endogenous Cre | Embryonic lethal | | Prrx1-Cre, Rosa26 LSL-FUS-CHOP/+ | Endogenous Cre | 4 | 11 | 36.4% | | Prrx1-CreER-GFP, Rosa26 LSL-FUS-CHOP/+ | CreER, IM 4-OHT | 2 | 6 | 33.3% | | aP2-CreER, Rosa26 LSL-FUS-CHOP/+ | CreER, IP tamoxifen | 0 | 9 | 0.0% |
| | Site-specific Cre models | | Rosa26 LSL-FUS-CHOP/+ | Adenovirus | 0 | 13 | 0.0% | | Rosa26 LSL-FUS-CHOP/+, p53fl/fl | Adenovirus | 2 | 11 | 18.2% | | Rosa26 LSL-FUS-CHOP/LSL-FUS-CHOP | Adenovirus | 0 | 29 | 0.0% | | Rosa26 LSL-FUS-CHOP/LSL-FUS-CHOP, p53fl/fl | Adenovirus | 7 | 29 | 24.1% | | Rosa26 LSL-FUS-CHOP/LSL-FUS-CHOP, pSECC-sgp53 | CRISPR, electroporation | 21 | 21 | 100.0% | | Rosa26 LSL-FUS-CHOP/LSL-FUS-CHOP, pSECC-sgScr | CRISPR, electroporation | 0 | 3 | 0.0% |
| | In vivo CRISPR model | | 129/SvJ, AdFC-Cas9 | CRISPR, Adenovirus | 0 | 31 | 0.0% | | p53fl/fl, AdCre, AdFC-Cas9 | CRISPR/Cre, Adenovirus | 0 | 4 | 0.0% |
| | UPS model | | LSL-KrasG12D/+, p53fl/fl | Adenovirus | 10 | 10 | 100.0% |
|
|
